Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II study of sunitinib in relapsed male germ cell tumors
2007-004981-42Phase 2Completed
- Sponsor
- Národný onkologický ústav
- Start
- Apr 2008
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of sunitinib in germ cell tumor (GCT), sponsored by Národný onkologický ústav. Primary endpoint: Twelve-month post treatment initiation continuous progression-free survival rate. Started Apr 2008; status: completed.
02
Drugs
sunitinib
03
Conditions
germ cell tumor (GCT)
Beyond the preview
Go deeper on 2007-004981-42.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2007-004981-42.